| Document |
Document Title |
|
WO/2024/153225A1 |
The disclosure is directed to novel ALPK1 inhibitors having the Formula (I), or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, a stable isotopic variant, a prodrug, or a crystal form thereof. The disclosure is also directe...
|
|
WO/2024/153105A1 |
Disclosed in the present invention are a five-membered heterocyclic compound and a pharmaceutical composition thereof and the use thereof. The structure of the five-membered heterocyclic compound is as shown in formula (I). A stereoisome...
|
|
WO/2024/153134A1 |
Disclosed are five-membered heterocyclic compounds and pharmaceutical use thereof. The compounds represented by formula (I) or pharmaceutically acceptable salts thereof have a potent agonistic effect on PPARα and PPARδ, so that the com...
|
|
WO/2023/083983A9 |
The present invention thus provides a novel family of liposomal compositions (nanocarriers), hereinafter referred to as Tetra-Acidosomes, comprising natural tetrameric acid (TA) lipids and/or novel chemically functionalized tetrameric ac...
|
|
WO/2024/147139A1 |
The invention provides 1,2-derivated phenylene compounds and composition comprising them and uses thereof in the method of treatment and prevention of diseases and conditions associated with or aggravated by impaired mitophagy or oxidati...
|
|
WO/2024/145483A1 |
Disclosed herein are compounds that inhibit RNA modifying enzymes, such as METTL3, and thus can be used for treating and/or preventing diseases, such as cancers. Also disclosed herein are methods for making and using the disclosed compou...
|
|
WO/2024/140595A1 |
Disclosed in the present invention are a tricyclic compound, a pharmaceutical composition thereof and the use thereof. Specifically, disclosed in the present invention is a compound as represented by formula (I) or a pharmaceutically acc...
|
|
WO/2024/143336A1 |
In the present invention, a compound represent by formula Z-I has excellent bactericidal activity and has excellent stability. (In the formula: Q1 represents a phenyl group, or the like; Q2 represents a phenyl group, or the like; partial...
|
|
WO/2024/137671A1 |
Disclosed herein are compounds according to Formula (I). Compounds according to Formula I inhibit PKMYT1 and are useful for the treatment of cancer and other disease. The present invention also provides methods for making compounds as me...
|
|
WO/2024/124439A1 |
An antibacterial and anti-tumor synergist, and a synthesis method therefor and a use thereof. According to an antibacterial and anti-tumor synergist compound, the drug sensitivity of bacteria and tumor cells to antibiotics and anti-cance...
|
|
WO/2024/126407A1 |
The current invention relates to compounds of the formula (I) wherein the substituents are as defined in claim 1, to processes and methods for preparing compounds of formula (I), to agrochemical compositions comprising compounds of formu...
|
|
WO/2024/121779A1 |
The invention relates to compounds of Formula (I) (I) and pharmaceutically acceptable salts thereof as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to inte...
|
|
WO/2024/121301A1 |
The present invention relates to a process for the preparation of sitagliptin.
|
|
WO/2024/114106A1 |
The present application discloses a sulfentrazone intermediate synthesis method. By adding a composite catalyst, a compound as shown in formula II is subjected to a chlorination reaction in the presence of a solvent to synthesize a compo...
|
|
WO/2024/115641A1 |
The present invention relates to a series of noncovalent Keap1-Nrf2 small-molecule inhibitors and their use as medicaments. The series comprises novel small-molecule analogues with strong affinity for the Keap1 Kelch domain and ability t...
|
|
WO/2024/109917A1 |
The present invention relates to a triazole derivative and an application thereof in medicine, in particular to a compound described in general formula (I) or stereoisomers, tautomers, deuterates, solvates, prodrugs, metabolites, pharmac...
|
|
WO/2024/110999A1 |
The present invention provides an improved and industrially advantageous process for the preparation of highly pure sulfentrazone having assay more than 97% and impurity A (chloromethyl) and impurity B (chlorofluoromethyl) each present i...
|
|
WO/2024/109736A1 |
The present application provides a compound as shown in formula (0), a pharmaceutical composition containing same, a synthesis method therefor and a use thereof. The compound of the present application can significantly reduce the integr...
|
|
WO/2024/112656A1 |
Compositions and methods are provided for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and pulmonary arterial hypertension (PAH) by administration of an effective dose of a protein tyrosine kinase (PTK) inhibitor that inh...
|
|
WO/2024/103246A1 |
The present invention provides a polymer structure and a use thereof. The polymer structure comprises a substrate and a light shielding layer covering at least part of the surface of the substrate; the substrate comprises a first polymer...
|
|
WO/2024/095005A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: wherein V, W, X, Y, Z, A1, A2, A3, A4, A5, A6, A7, A8, A9 and R3 are as defined in the specification,...
|
|
WO/2024/088343A1 |
A novel Kv1.3 channel (or KV1.3) inhibitor, which can be used for preventing and/or treating diseases related to the Kv1.3 channel (or Kv1.3), including immune and inflammatory diseases, such as: multiple sclerosis, inflammatory bowel di...
|
|
WO/2024/086317A1 |
The present disclosure relates to compounds of formula (I) and compositions comprising the same. The disclosure further relates to methods of treating cognitive impairment.
|
|
WO/2024/083670A2 |
The invention relates to bromine- or iodine-para-substituted [(1,5-diphenyl-1H-1,2,4-triazol-3-yl)oxy]acetic acid derivatives and their salts, to agents for protecting useful plants or crop plants comprising them, to methods for producin...
|
|
WO/2024/083671A1 |
The invention relates to bromine- or iodine-para-substituted [(1,5-Diphenyl-1H-1,2,4-triazol-3-yl)oxy]acetic acid derivatives and salts thereof, protection agents comprising them, for useful plants or crop plants, and methods for produci...
|
|
WO/2024/081311A1 |
The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition or degradation of Cbl-b, and the treatment of Cbl-b-mediated disorders. Formula (I)
|
|
WO/2024/078646A1 |
A method for preparing (R)-tebuconazole by means of an enzyme chemical process, comprising: firstly, by taking the whole cell of recombinant bacterium E. coli/Rpeh expressing an epoxide hydrolase as a catalyst, resolving a racemic tebuco...
|
|
WO/2024/075825A1 |
The present invention addresses the problem of providing a novel compound that has an OX2R agonist activity. The present invention pertains to a cyclopentane compound represented by formula (I) or a pharmacologically acceptable salt th...
|
|
WO/2024/074126A1 |
Provided are a 4-methylsulfonylbenzamide compound having a structure represented by general formula (I) and having a sulfur-containing substituent at position 3, a stereoisomer thereof, an agriculturally acceptable salt thereof, a prepar...
|
|
WO/2024/077292A2 |
Described are synthetic compounds having anti-inflammatory properties and optionally analgesic properties. These compounds are derivatives of FDA-approved anti-inflammatory, such as ibuprofen and indomethacin, and can be formed using rea...
|
|
WO/2024/067784A1 |
Provided are an amorphous form and 16 crystal forms of a compound represented by formula (I). The crystal forms are named in order from crystal form A to crystal form P. Also provided is a preparation method for the amorphous form and po...
|
|
WO/2024/062363A1 |
The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful as CBL-b inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and...
|
|
WO/2024/064778A2 |
The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein R1, X, and n are defined herein, their pharmaceutical compositions, and methods of use for treating diseases that are vulnerab...
|
|
WO/2024/063147A1 |
The present invention provides a compound represented by formula (I) and useful as a pharmaceutical product, or a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition for the treat...
|
|
WO/2024/057213A1 |
The present invention relates to a process for preparation of Ipconazole and its intermediates. The present invention provides a simple, cost-effective and industrially viable process for preparation of Ipconazole and its intermediates. ...
|
|
WO/2024/050815A1 |
Provided is the use of heteroaromatic ring compounds in nucleic acid tests. Particularly provided are the use of heteroaromatic ring compounds as a nucleic acid protective agent in nucleic acid tests, a method for inhibiting degradation ...
|
|
WO/2024/044813A1 |
The present invention relates to novel fluoroallylamine sulfone derivatives that are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for the treatment of a variety of indications, e.g., fibrosis, cancer an...
|
|
WO/2024/047227A1 |
The present invention relates to compounds of Formula (I) and (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical c...
|
|
WO/2024/033293A1 |
The present invention relates to acylhydrazides obtained in situ by enzymatic hydrolysis of the parent prodrug 2-(difluoromethyl)- or 2-(trifluoromethyl)-1,3,4- oxadiazole, in histone deacetylase 6 (HDAC6).
|
|
WO/2024/031192A1 |
Provided herein is the synthesis of a folate phosphoramidite of Formula I and the use of the folate phosphoramidite in the preparation of folate-siRNAs. Also provided are methods to silent expression of a target gene in a cell that expre...
|
|
WO/2024/028363A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2024/028364A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2024/028169A1 |
The present invention relates to novel thiophenolic compounds (I) which are useful in the treatment of proliferative and/or hyper-proliferative diseases. Preferably, the compounds of the present invention are endowed with inhibitory acti...
|
|
WO/2024/030960A2 |
Methods and systems and compounds and agents for the induction or modulation of ferroptosis in a cell, a tissue, or a tumor in a subject are provided. Various agents and compounds are described. Various methods of administration are desc...
|
|
WO/2024/030651A1 |
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, sp...
|
|
WO/2024/025797A1 |
A composition includes at least one pH adjuster, at least one chelating agent, at least one anionic surfactant, at least one nitrogen containing heterocycle, at least one alkylamine compound, and an aqueous solvent, wherein the compositi...
|
|
WO/2024/024866A1 |
[Problem] The present invention provides: a water-based coating composition containing an ultraviolet ray absorber, which has excellent transparency and satisfactorily blocks ultraviolet ray; and a method for producing the water-based co...
|
|
WO/2024/025907A1 |
The present disclosure provides compounds of Formula (IA) and their pharmaceutical compositions: The compounds and compositions are useful for inhibiting the activity of plasma kallikrein, and they are useful in therapy and in methods of...
|
|
WO/2024/019014A1 |
Provided as a precursor of a radioactive halogen-labeled compound is a compound represented by general formula (I) [in the formula, R1 represents a leaving group that can undergo nucleophilic substitution by a halide ion, R2 represents a...
|
|
WO/2024/017150A1 |
Provided in the present application is a method for synthesizing deucravacitinib. The method comprises: subjecting the compound of formula (I) to chlorination and to electrophilic substitution with the compound of formula (VI) to synthes...
|
